Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol-triacetate-ester has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
This compound is resveratrol with its phenolic hydroxyl groups capped as acetate esters. Carboxylesterases in the gut wall and liver cleave the acetates and release resveratrol itself, which is the species that does the downstream work. Any activity attributed to the ester is activity of the resveratrol it liberates. The two are not additive, they are the same molecule at different points in the same sequence.
Free resveratrol is cleared very quickly by sulfotransferases and UDP-glucuronosyltransferases in the intestinal wall, which is the main reason its plasma levels stay low. Quercetin is a substrate and inhibitor of the same enzymes and competes for them. The result is a measured change in resveratrol pharmacokinetics, which is not the same as a change in any outcome.
Piperine inhibits intestinal UDP-glucuronosyltransferase activity and slows first-pass conjugation of polyphenols. Acetylated stilbenes still face that conjugation once the esterases have freed the parent, so the pairing addresses a real bottleneck. Piperine inhibits drug-metabolising enzymes broadly, which is a reason to check anything else being taken.
Acetylation raises lipophilicity and lowers aqueous solubility further than the parent stilbene, so dissolution becomes the rate-limiting step. Phospholipid dispersion keeps the compound in a solubilised state through the gut. This addresses dissolution, not metabolism.
Phospholipid complexes are the standard formulation answer for poorly soluble polyphenols and give measurably higher plasma appearance. The acetylated stilbene is a good candidate because its solubility problem is worse than the parent's. Absorption is the endpoint being changed here.
A lipid vehicle promotes bile release and micelle formation, which is what a highly lipophilic acetylated stilbene needs to stay in solution through the small intestine. Taking it with a fat-containing meal does much the same. Dry powder taken on an empty stomach is the worst case for a compound like this.
Same reasoning as with other NAD precursors, the stilbene sits on the enzyme side and the precursor on the cosubstrate side. It is a coherent mechanistic story with thin human support. Read it as pathway logic rather than a demonstrated combination effect.
Pterostilbene is the dimethyl ether of resveratrol and resists phase II conjugation far better, so it persists longer in plasma. Combining it with an acetylated resveratrol prodrug gives two stilbenes with different clearance profiles. They also compete for the same conjugating enzymes, so the interaction runs in both directions.
Free stilbene phenols oxidise readily once the acetate caps are removed. Ascorbate in the same formulation lowers oxidative loss during storage and in the gut lumen. The benefit here is chemical stability rather than a physiological synergy.
Resveratrol inhibits platelet aggregation in laboratory systems, and long-chain omega-3 fatty acids do so through eicosanoid shifts. Stacking them at high intakes is worth flagging for anyone already on anticoagulant or antiplatelet medication. This is a caution rather than a benefit claim.
Nothing specific on file for 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol-triacetate-ester. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.